Search research articles
Contact Us
Filters
Showing results (61-70 of 119) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
British Journal of Haematology
|
July 13, 2017
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
Timothy P Hughes, Eduardo Munhoz, Marco Aurelio Salvino, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 119) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2021
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, et al.
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Blood Advances
|
October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma
Constantine S Tam, Hang Quach, Andrew Nicol, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
P Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
British Journal of Haematology
|
July 13, 2017
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
Timothy P Hughes, Eduardo Munhoz, Marco Aurelio Salvino, et al.
Blood Advances
|
May 13, 2024
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16
Peter Mollee, John Reynolds, Wojt Janowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
Meletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Internal Medicine Journal
|
March 7, 2023
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia
Shirlene Sim, Anna Kalff, Gina Tuch, et al.
Page
of 12